Non-Discrimination Notice

Previously Completed Clinical Trials

ADAPT Study: This study is looking to see if an experimental treatment is effective against kidney cancer.

Afferent Pharmaceuticals: A Four-Week, Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Female Subjects with Interstitial Cystitis /Bladder Pain Syndrome

Allergan: A study of the safety and efficacy of a single treatment with one dose level of Botox in patients with Urinary Incontinence due to Neurogenic Detrusor Over Activity.

Allergan Protocol 113: A study evaluating the use of Botox in Overactive Bladder.

Allergan Protocol 125: A Study Evaluating the Efficacy and Safety of BOTOX® and Solifenacin in Patients with Overactive Bladder and Urinary Incontinence.

Amgen: Protocol 20080560: A Double-blind, Placebo-controlled Study to Evaluate New or Worsening Lens Opacifications in Subjects with Non-metastatic Prostate Cancer Receiving Denosumab for Bone Loss due to Androgen-Deprivation Therapy

Astellas: Protocol 905-UC-050: A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multi-Center Study to Assess Efficacy and Safety of VESIcare (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy.

Astellas Pharmaceuticals: A Randomized, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder

Augmenix: Evaluation of SpaceOAR™ System when used to Create Space Between the Rectum and Prostate in Men Undergoing Image Guided – Intensity Modulated Radiation Therapy (IG-IMRT) for Localized Stage T1-T2 Prostate Cancer: A Randomized, Multicenter, Parallel Arm Controlled Clinical Study

C Deffence: A study evaluating the use of a vaccine in patients at risk for C Dif infection.

Carolina Research Professionals Protocol 01: A study evaluating the effects of concurrent administration of Radium-223 and Abiraterone Acetate plus Prednisone.

Dendreon N10-1: This study will benefit others in the future. This may prevent re-occurrence or slow the progression of your bladder cancer with or without extension to the ureter or kidney in the future. 

Exosome Gene Protocol ECT2011-001: Correlation of urine with exosome gene including results of prostate cancer followed by clinical outcome post radical prostatectomy.

Exosome Gene Protocol ECT2011-002: Correlation of urine with exosome gene signatures including the results of a prostate needle biopsy. 

GlaxoSmithKline: A Randomized Double-Blind, Placebo-Controlled study of the efficacy and safety of Dutasteride 0.5mg for four years to reduce the risk of biopsy-detectible prostate cancer.

GlaxoSmithKline: A Randomized Double-Blind, Placebo-Controlled study assessing the efficacy and safety Avodart has in extending the time to progression of low risk, localized prostate cancer.

GlaxoSmithKline: A Randomized Double-Blind, Parallel Group comparing Casodex 50mg plus placebo to Casodex 50mg plus Dutasteride 3.5mg.

GTX: A Randomized, Double-Blind, Placebo-Controlled study of Toremifene Citrate for the prevention of bone fractures in men with prostate cancer on ADT.

GTX: A Randomized, Double-Blind, Placebo-Controlled efficacy and safety study of Toremifene Citrate for the prevention of Prostate Cancer in men with high grade PIN.

GTX G200705: Phase II, open label, dose finding study of the effect of GTx-758 on total and free testosterone levels in men with prostate cancer compared to a luteinizing hormone releasing hormone agonist.

GTX G200707: Open label study of the effect of GTx-758 on serum PSA and free testosterone levels in men with castration resistant prostate cancer and maintained on androgen deprivation therapy.

GTX G200710: Phase II, open label, loading and maintenance dose finding study of GTx-758 in men with prostate cancer.

GTX G200712: This study will benefit others in the future. This may slow the clinical progression of your metastatic prostate cancer in the future.

Lilly: An Open-Label study to evaluate the efficacy and safety of Tadalafil administered “On Demand” to men of various populations with erectile dysfunction.

Medivation STRIVE: A Multicenter Phase 2, Randomized, Double-Blind, Efficacy and Safety Study of Enzalutamide vs. Bicalutamide in Men with Prostate Cancer who have Failed Primary Androgen Deprivation Therapy

OPKO Diagnostics: The OPKO Diagnostics 4Kscore™ as a Predictor of Prostate Cancer Prior to Biopsy

Pfizer: A Randomized, Double-Blind, Placebo-Controlled study to evaluate the efficacy and safety of Fesoterodine.

Pfizer: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group study to evaluate the efficacy and safety of Fesoterodine Flexible Dose Regimen in patients with OAB.

Pfizer: A Double-Blind, Placebo Controlled study to evaluate the clinical efficacy and safety of Tolterodine ER 4mg in men who have frequency and urgency.

Pfizer: A 14 week randomized parallel group placebo-controlled double-blind multicentre study of fesoterodine 8 mg in overactive bladder patients with sub-optimal response to tolterodine 4 mg ER.

Predictive Biosciences: Bladder Cancer recurrence surveillance Trial

Predictive Biosciences: Hematuria evaluation trial Watson: Tolerability of GNRH analogue administration in patients with advanced Prostate Cancer Trelstar vs. Eligard.

Qualigen: The safety and efficiency of using the Qualigen Fast Pack PSA immunoassay to detect prostate cancer in males over 50.